Program
pirfenidone
Also written as “Pirfenidone”, “Pirfenidone Modified-Release Tablets” and “Deupirfenidone”.
Its studies are mostly in Idiopathic Pulmonary Fibrosis · Lung Injury · Lung Diseases, Interstitial · Pulmonary Fibrosis · COVID-19, led by 6 companies.
Drug pagePirfenidone: every studyMany companies study it; this page follows only the 29 they lead. All 102 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Rocheits history only | 120 open or running | phase 4since Nov 4, 2015 | Mar 24, 2004 | none ahead |
| GNI Groupits history only | 72 open or running | phase 3since Feb 26, 2019 | Nov 18, 2014 | Dec 30, 2026phase 3 · NCT07388680 |
| PureTechits history only | 52 open or running | phase 3since Dec 8, 2025 | Jan 21, 2020 | Nov 2029phase 3 · NCT07284602 |
| Overseas Pharmaceuticalsits history only | 30 open or running | phase 1since Aug 22, 2024 | Aug 22, 2024 | none ahead |
| beijing-kawin-technology-share-holding-co-ltdits history only | 10 open or running | phase 2since Dec 30, 2011 | Dec 30, 2011 | none ahead |
| grupo-medifarma-s-a-de-c-vits history only | 10 open or running | phase 3since Jul 6, 2015 | Jul 6, 2015 | none ahead |
Also a collaborator on its studies: Clinipace Worldwide, Novotech (Australia) Pty, Shanghai Genomics and GNI-EPS Pharmaceuticals, Inc. (GNI Group).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 13 studies since Mar 24, 2004.
- Mar 31, 2017Phase 2 study in Lung Diseases, InterstitialHoffmann-La Roche · NCT03099187 · 253 enrolled · Australia, Belgium, Canada and more
- Jun 26, 2017Phase 3 study in Idiopathic Pulmonary FibrosisHoffmann-La Roche · NCT03208933 · 60 enrolled · Russian Federation
- Feb 26, 20192 phase 3 studiesGNI Group · NCT03857854, NCT03856853
- Apr 2, 2019Phase 2 study in Radiation-induced Lung InjuryGNI Group · NCT03902509 · 126 enrolled · China
- Oct 10, 2019Phase 1 study in Renal InsufficiencyGNI Group · NCT04126538 · 24 enrolled · China
- Jan 21, 2020PureTech’s first study: phase 2 study in LymphedemaNew to PureTechPureTech · NCT04243837 · 50 enrolled · United States, Australia
- Dec 2, 2020Phase 2 study in COVID-19PureTech · NCT04652518 · 185 enrolled · United States, Argentina, Brazil and more
- Feb 17, 2022Phase 3 study in PneumoconiosisGNI Group · NCT05288179 · 272 planned · China
- Apr 2, 2022Phase 2 study in Idiopathic Pulmonary FibrosisPureTech · NCT05321420 · 240 enrolled · United States, Argentina, Chile and more
- Aug 22, 2024Overseas Pharmaceuticals’ first study: phase 1 study in Idiopathic Pulmonary FibrosisNew to Overseas PharmaceuticalsOverseas Pharmaceuticals · NCT06569381 · 18 enrolled · China
- Sep 6, 20242 phase 1 studies in Idiopathic Pulmonary FibrosisOverseas Pharmaceuticals · NCT06589921, NCT06588517
- Nov 17, 2025Phase 3 study in Radiation-induced Lung InjuryGNI Group · NCT07388680 · 298 planned · China
- Dec 8, 2025Phase 3 study in Idiopathic Pulmonary FibrosisPhase 3 reachedPureTech · NCT07284602 · 1,100 planned · United States, Canada
- Feb 19, 2026Phase 1 study in Pharmacokinetic AnalysisPureTech · NCT07456800 · 116 enrolled · United States
Ahead
- Dec 30, 2026Primary completion: phase 3 study in Radiation-induced Lung InjuryGNI Group · NCT07388680
- Nov 2029Primary completion: phase 3 study in Idiopathic Pulmonary FibrosisPureTech · NCT07284602
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 29 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07456800Pharmacokinetic Analysis · United States | 1 | Completed | PureTech | Jan 1, 2022 | 116 |
| NCT07284602Idiopathic Pulmonary Fibrosis · United States, Canada | 3 | Recruiting | PureTech | Nov 2029 | 1,100 |
| NCT07388680Radiation-induced Lung Injury · China | 3 | Recruiting | GNI Group | Dec 30, 2026 | 298 |
| NCT06589921Idiopathic Pulmonary Fibrosis · China | 1 | Completed | Overseas Pharmaceuticals | Sep 5, 2023 | 24 |
| NCT06588517Idiopathic Pulmonary Fibrosis · China | 1 | Completed | Overseas Pharmaceuticals | Apr 19, 2024 | 12 |
| NCT06569381Idiopathic Pulmonary Fibrosis · China | 1 | Completed | Overseas Pharmaceuticals | Oct 1, 2024 | 18 |
| NCT05321420Idiopathic Pulmonary Fibrosis · United States, Argentina, Chile and more | 2 | Active, not recruiting | PureTech | Oct 15, 2024 | 240 |
| NCT05288179Pneumoconiosis · China | 3 | Recruiting | GNI Group | Sep 30, 2026 | 272 |
| NCT04652518COVID-19 · United States, Argentina, Brazil and more | 2 | Terminated | PureTech | Jun 28, 2022 | 185 |
| NCT04243837Lymphedema · United States, Australia | 2 | Terminated | PureTech | Sep 9, 2022 | 50 |
| NCT04126538Renal Insufficiency · China | 1 | UNKNOWN | GNI Group | Nov 25, 2021 | 24 |
| NCT03902509Radiation-induced Lung Injury · China | 2 | Completed | GNI Group | Dec 4, 2023 | 126 |
| NCT03857854Dermatomyositis Interstitial Lung Disease (Dm-ILD) · China | 3 | UNKNOWN | GNI Group | Feb 2021 | 152 |
| NCT03856853Systemic Sclerosis-associated Interstitial Lung Disease (Ssc-ild) · China | 3 | UNKNOWN | GNI Group | Feb 10, 2021 | 144 |
| NCT03208933Idiopathic Pulmonary Fibrosis · Russian Federation | 3 | Completed | Hoffmann-La Roche | Nov 13, 2019 | 60 |
| NCT03099187Lung Diseases, Interstitial · Australia, Belgium, Canada and more | 2 | Completed | Hoffmann-La Roche | Nov 21, 2018 | 253 |
| NCT02648048Idiopathic Pulmonary Fibrosis · United States, Germany | 1 | Completed | Hoffmann-La Roche | Nov 30, 2016 | 21 |
| NCT02598193Idiopathic Pulmonary Fibrosis · United States, Canada, Denmark and more | 4 | Completed | Hoffmann-La Roche | May 16, 2017 | 89 |
| NCT02525484Healthy Volunteer · United States | 1 | Completed | Hoffmann-La Roche | Aug 2015 | 44 |
| NCT02496182Alveolitis, Extrinsic Allergic · Mexico | 3 | UNKNOWN | grupo-medifarma-s-a-de-c-v | Jan 2016 | 60 |
| NCT02296281Radiation Pneumonitis | 2 | UNKNOWN | GNI Group | Jun 2016 | 48 |
| NCT01933334Scleroderma, Systemic · United States, Canada, Italy | 2 | Completed | Hoffmann-La Roche | Sep 2014 | 63 |
| NCT01872689Idiopathic Pulmonary Fibrosis · United States, Australia, Belgium and more | 2 | Completed | Hoffmann-La Roche | Jul 28, 2017 | 505 |
| NCT01504334Idiopathic Pulmonary Fibrosis · China | 2 | UNKNOWN | beijing-kawin-technology-share-holding-co-ltd | Nov 2012 | 80 |
| NCT01366209Idiopathic Pulmonary Fibrosis · United States | 3 | Completed | Hoffmann-La Roche | Feb 2014 | 555 |
| NCT00662038Idiopathic Pulmonary Fibrosis · United States | 3 | Completed | Hoffmann-La Roche | Feb 2016 | 1,058 |
| NCT00287729Idiopathic Pulmonary Fibrosis · United States | 3 | Completed | Hoffmann-La Roche | Nov 2008 | 344 |
| NCT00287716Idiopathic Pulmonary Fibrosis · United States | 3 | Completed | Hoffmann-La Roche | Nov 10, 2008 | 435 |
| NCT00080223Idiopathic Pulmonary Fibrosis · United States | 2 | Completed | Hoffmann-La Roche | Apr 30, 2015 | 83 |
How it is read
Names in the registry
- “Pirfenidone”, 26 entries
- “Pirfenidone Modified-Release Tablets”, 4 entries
- “Deupirfenidone”, 3 entries
- “pirfenidone capsule”, 2 entries
- “pirfenidone”, 2 entries
Conditions, from the studies’ own filings
- Idiopathic Pulmonary Fibrosis, 21 studies
- Lung Injury, 2 studies
- Lung Diseases, Interstitial, 2 studies
- Pulmonary Fibrosis, 1 study
- COVID-19, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.